SPOTLIGHT -
Olaparib Plus Abiraterone Improves rPFS Across Biomarker Groups for mCRPC
Fred Saad, MD, FRSC, discusses the findings of a biomarker analysis of the PROpel trial in patients with metastatic castration-resistant prostate cancer.
Key Biomarkers to Test for in Metastatic CRPC
Fred Saad, MD, FRSC, discusses the key biomarkers looked at in an analysis of the phase 3 PROpel trial analyzing olaparib plus abiraterone to treat patients with metastatic castration resistant prostate cancer.
Dr. Saad Discusses the Benefit of Radium-223 in Patients with mCRPC
Fred Saad, MD, FRCS, University of Montreal, discusses the benefit of radium-223 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
